Zobrazeno 1 - 10
of 370
pro vyhledávání: '"Judith M. Bliss"'
Autor:
Eugene F. Schuster, Elena Lopez-Knowles, Anastasia Alataki, Lila Zabaglo, Elizabeth Folkerd, David Evans, Kally Sidhu, Maggie Chon U. Cheang, Holly Tovey, Manuel Salto-Tellez, Perry Maxwell, John Robertson, Ian Smith, Judith M. Bliss, Mitch Dowsett
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given the limited understanding of intrinsic resi
Externí odkaz:
https://doaj.org/article/ac7abf0f898945ac9498001b487931f6
Autor:
Judith M. Bliss, Holly Tovey, Abigail Evans, Chris Holcombe, Kieran Horgan, Elizabeth Mallon, Raghavan Vidya, Anthony Skene, Andrew Dodson, Margaret Hills, Simone Detre, Lila Zabaglo, Jane Banerji, Lucy Kilburn, James P. Morden, John F. R. Robertson, Ian Smith, Mitch Dowsett, the POETIC Trialists
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-16 (2023)
Abstract Purpose Ki67 assessed at diagnosis (Ki67baseline) is an important prognostic factor in primary oestrogen receptor-positive (ER +) breast cancer. Proportional change in Ki67 after 2 weeks (∆Ki672week) is associated with clinical benefit fro
Externí odkaz:
https://doaj.org/article/46abcee1eee44a268049c2e73c029025
Autor:
Elena Lopez-Knowles, Simone Detre, Margaret Hills, Eugene F. Schuster, Maggie C. U. Cheang, Holly Tovey, Lucy S. Kilburn, Judith M. Bliss, John Robertson, Elizabeth Mallon, Anthony Skene, Abigail Evans, Ian Smith, Mitch Dowsett
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-10 (2022)
Abstract Background In clinical practice, oestrogen receptor (ER) analysis is almost entirely by immunohistochemistry (IHC). ASCO/CAP recommends cut-offs of
Externí odkaz:
https://doaj.org/article/b69c05c893f24935a330283cbc7187d8
Autor:
Claire Snowdon, Sarah Kernaghan, Laura Moretti, Nicholas C. Turner, Alistair Ring, Katie Wilkinson, Sue Martin, Stephanie Foster, Lucy S. Kilburn, Judith M. Bliss
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Platform trial designs are used increasingly in cancer clinical research and are considered an efficient model for evaluating multiple compounds within a single disease or disease subtype. However, these trial designs can be chall
Externí odkaz:
https://doaj.org/article/95aec4e90bb041c8a063405e0216014f
Autor:
Indrani S. Bhattacharya, Joanne S. Haviland, Lesley Turner, Hilary Stobart, Ada Balasopoulou, Liba Stones, Anna M. Kirby, Cliona C. Kirwan, Charlotte E. Coles, Judith M. Bliss, on behalf of the PRIMETIME Trialists
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background For patients with early breast cancer considered at very-low risk of local relapse, risks of radiotherapy may outweigh the benefits. Decisions regarding treatment omission can lead to patient uncertainty (decisional conflict), whi
Externí odkaz:
https://doaj.org/article/7a1b5a5ff7bc4201b41f218ffc1c17bc
Autor:
Belinda Kingston, Rosalind J. Cutts, Hannah Bye, Matthew Beaney, Giselle Walsh-Crestani, Sarah Hrebien, Claire Swift, Lucy S. Kilburn, Sarah Kernaghan, Laura Moretti, Katie Wilkinson, Andrew M. Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Jorge S. Reis-Filho, Michael Hubank, Iris Faull, Kimberly C. Banks, Richard B. Lanman, Isaac Garcia-Murillas, Judith M. Bliss, Alistair Ring, Nicholas C. Turner
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Circulating tumour DNA can provide useful information on disease burden. Here, the authors analysed circulating tumour DNA from 800 patients from a breast cancer clinical trial and investigate the subclonal nature of the disease, and identify DNA mut
Externí odkaz:
https://doaj.org/article/5f176e5d5bcb4792adb4ec1effb35966
Autor:
John F. R. Robertson, Angelo Di Leo, Stephen Johnston, Stephen Chia, Judith M. Bliss, Robert J. Paridaens, Jasmine Lichfield, Ian Bradbury, Christine Campbell
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-12 (2021)
Abstract Endocrine therapy (ET) is recommended as first-line therapy for the majority of patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative advanced breast cancer (ABC); however, the efficacy of ET in patients wit
Externí odkaz:
https://doaj.org/article/d7d894e65aa140f485dd6e6e9833028a
Autor:
Neha Chopra, Holly Tovey, Alex Pearson, Ros Cutts, Christy Toms, Paula Proszek, Michael Hubank, Mitch Dowsett, Andrew Dodson, Frances Daley, Divya Kriplani, Heidi Gevensleben, Helen Ruth Davies, Andrea Degasperi, Rebecca Roylance, Stephen Chan, Andrew Tutt, Anthony Skene, Abigail Evans, Judith M. Bliss, Serena Nik-Zainal, Nicholas C. Turner
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Defects in homologous recombination (HR) are found in some triple negative breast cancers, suggesting they may be sensitive to PARP inhibitors. In this phase II clinical trial of the PARP inhibitor rucaparib, changes in Ki67 levels did not correlate
Externí odkaz:
https://doaj.org/article/16335d8252804f3a9e5594503bbf84fa
Autor:
Qiong Gao, Elena López-Knowles, Maggie Chon U. Cheang, James Morden, Ricardo Ribas, Kally Sidhu, David Evans, Vera Martins, Andrew Dodson, Anthony Skene, Chris Holcombe, Elizabeth Mallon, Abigail Evans, Judith M. Bliss, John Robertson, Ian Smith, Lesley-Ann Martin, Mitch Dowsett, on behalf of the POETIC Trial Management Group and Trialists
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-20 (2019)
Abstract Background Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. In this study, we sought to investigate the impact of aromatase inhibitor (AI) therapy on gene expression and identify gene
Externí odkaz:
https://doaj.org/article/40e602dbc4434a5ab9bdce77cea2c9ef
Autor:
Susana Banerjee, Holly Tovey, Rebecca Bowen, Elizabeth Folkerd, Lucy Kilburn, Jennifer McLachlan, Marcia Hall, Nina Tunariu, Ayoma Attygalle, Joao Paulo Da Silveira Nogueira Lima, Sophie Perry, Peter Chatfield, Margaret Hills, Stan Kaye, Gert Attard, Mitch Dowsett, Judith M. Bliss
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor abiraterone irreversibly inhibits
Externí odkaz:
https://doaj.org/article/573e022757c443b698c2911c247d9712